Health Insurance (Quality Assurance Activity – Australian Corneal Graft Registry) Declaration 2025

The declaration rests on a small set of interlocking concepts described in the Schedule and in the instrument’s short Part 1 provisions.

• Quality assurance activity: The core legal concept the instrument engages is a “quality assurance activity” under Part VC of the Health Insurance Act 1973. Clause 5 declares the Schedule’s activity to be such an activity, insofar as it relates to health services provided in Australia. The instrument itself does not define Part VC’s terms; it imports the concept by reference to the Act (clause 3).

• Data collection and aggregation: The Schedule describes the ACGR objective as collecting patient and surgeon data about corneal transplantation, aggregating and analysing those data, and returning de-identified, aggregated performance information. The Schedule lists the types of data collected: demographic recipient data, limited donor data, surgical procedure information, and follow-up outcome data collected at set intervals (12-18 months, and additional postal follow-up at 12-36 month intervals) until graft failure, recipient death, or loss to follow-up.

• Consent and withdrawal: The Schedule specifies that graft recipients provide consent to their surgeon for data submission to the ACGR. Consent is recorded initially on the registration form and may be withdrawn from the registry at any time. The Schedule also requires that a minimum dataset be submitted to the Australian Institute of Health and Welfare (AIHW) at five-year intervals for linkage with the National Death Index, a linkage that proceeds where consent has been provided.

• Governance and oversight: The registry is run by Flinders University staff; an Advisory Board of clinicians and scientists oversees registry management; and the Southern Adelaide Human Research Ethics Committee oversees and regularly reviews the ACGR’s methods.

• Reporting and recipients of analysis: The Schedule identifies the parties to whom de-identified, aggregated outcomes are provided: ophthalmic surgeons, Eye Banks, the international transplantation community, DonateLife and the National Organ and Tissue Donation and Transplantation Authority, MSAC, and other interested parties.

• Operational status and change: The Schedule records operational details at the time of declaration: the registry holds over 47,000 records and current participation is 80-85%. It identifies a shift in submissions from paper-based forms to planned secure online submission to increase participation and expand datasets to reflect new transplantation techniques.

These concepts combine into a legal and operational package: a university-run clinical registry with governance oversight and patient-consent-based data collection, declared to be a statutory quality assurance activity under the Act so that the ACGR’s work is captured by Part VC’s legal framework.

The Schedule and Part 1 provisions identify the set of persons and entities that the declaration touches directly.

• Corneal graft recipients (patients): The registry collects demographic and follow-up data about recipients. Recipients provide consent via their surgeon for data submission to the ACGR and for a minimum dataset to be passed to AIHW for five-yearly linkage with the National Death Index. Recipients have the express right to withdraw consent and be withdrawn from the registry at any time (Schedule 1).

• Ophthalmic surgeons and other health professionals: Surgeons are the primary source of registry submissions; the Schedule states that retrospective and prospective registration is achieved through surgeon-submitted forms and follow-up postal information sent to the surgeon or alternative health practitioner. Surgeons therefore bear the practical tasks of obtaining consent, completing registration forms, and responding to follow-up requests.

• Eye Banks: The ACGR collects data from Eye Banks. The Schedule names Eye Banks as contributors and as recipients of aggregated performance information.

• Flinders University staff and the Advisory Board: Flinders University staff are named as conducting the ACGR. An Advisory Board of clinicians and scientists oversees management of the registry. These actors are decision-makers with responsibility for data collection, analysis, and reporting.

• Oversight and statutory bodies: The Southern Adelaide Human Research Ethics Committee is described as overseeing and regularly reviewing registry methods. The Schedule also identifies DonateLife, the National Organ and Tissue Donation and Transplantation Authority, and the Medical Services Advisory Committee (MSAC) as recipients of the aggregate outputs; they are therefore stakeholders in the registry’s findings and outputs.

• Australian Institute of Health and Welfare (AIHW) and National Death Index linkage: The AIHW will receive a minimum dataset at five-year intervals for linkage with the National Death Index, subject to consent. This introduces a linkage partner and national mortality dataset into the registry’s data ecosystem.

• International transplantation community and “other interested parties”: The Schedule identifies additional external stakeholders who receive de-identified aggregated outputs, including the international transplantation community.

• The Minister and Ministerial delegate: The declaration is made by the Minister’s delegate under subsection 124X(1) of the Act; by the instrument’s terms, execution and administrative decisions about the declaration reside with Commonwealth decision-makers acting under the statutory delegation framework.

Indirectly affected parties include suppliers and contractors who may provide secure online submission platforms, administrators who handle mailings for follow-up, and institutions that analyse or act on registry findings. The Schedule also flags that surgeons have indicated paper-based forms are a barrier to participation; the shift to online submission will affect the behaviour and administrative burden of clinicians and their practices.

The text makes explicit who is expected to supply and receive data, who oversees the methods, and who may access outputs. It also sets the duties of consent and the recipient’s right of withdrawal, placing responsibilities on clinicians who obtain consent and on Flinders University staff who manage submissions and governance.

The declaration outlines several duties and rights embedded in the operational description of the Australian Corneal Graft Registry in Schedule 1. The instrument itself is concise; it delegates much of the operational detail to the Schedule.

Key duties

• Duty to obtain consent: The Schedule requires that graft recipients provide consent to their surgeon for data submission to the ACGR. Consent is indicated on the registration form. The surgeon therefore has an operational duty to record consent on the registration form before data submission.

• Duty to submit a minimum dataset to AIHW: Where recipient consent is provided, the Schedule requires submission of a minimum dataset to the Australian Institute of Health and Welfare at five-year intervals for linkage with the National Death Index. This duty falls on the registry administrators (Flinders University staff) to provide the AIHW with the required dataset at the prescribed intervals, contingent on recipient consent.

• Duty to collect and follow up data: Flinders University staff collect the data on a voluntary basis from eye banks, surgeons, and health professionals, and seek follow-up information at regular intervals (12-18 months and 12-36 months at points the Schedule identifies) until graft failure, recipient death, or loss to follow-up.

• Governance duties: The Advisory Board consisting of clinicians and scientists oversees management of the registry. The Southern Adelaide Human Research Ethics Committee oversees and regularly reviews the registry’s methods. These bodies have supervisory duties in relation to methodology, ethical compliance, and review.

Key rights

• Patient withdrawal right: Recipients can withdraw their consent and be removed from the registry at any time. The Schedule states that consent “can also be withdrawn from the registry at any time”.

• Right to de-identified reporting: The Schedule commits that outcomes will always be reported in a de-identified, aggregated form. This is a right regarding the form in which individuals’ data may appear in outputs shared with third parties.

• Voluntary participation: The Schedule states that the ACGR collects information on a voluntary basis from contributing entities. This means that clinicians, eye banks and other health professionals are not statutorily compelled by this instrument alone to submit data; submission is a voluntary act under current practice as described.

Operational implications of these duties and rights

• The surgeon’s duty to obtain and record consent creates an administrative step at the point of care and locates procedural responsibility for registry participation with treating clinicians. Because withdrawal may occur at any time, recordkeeping systems and processes must be able to process withdrawal requests.

• The repository duty to submit the minimum dataset to AIHW at five-year intervals creates a periodic compliance obligation for the registry administrators, linked to consented records only.

• The Schedule’s requirement that outputs be de-identified and aggregated is framed as a protective rule within the registry’s reporting practices. The instrument does not prescribe de-identification standards, but it makes de-identification a stated, always-applied reporting principle.

• The voluntary character of contribution and the recorded intention to introduce secure online submission to improve participation interact with duties: the easier submission becomes, the greater the expected compliance among clinicians and the fuller the dataset feeding the registry outputs.

The declaration does not specify penalties for non-compliance with the described duties, nor does it prescribe enforcement mechanisms within the instrument itself. Any statutory protections, privileges or enforcement mechanisms attaching to declared quality assurance activities flow from Part VC of the Act (see clause 5), not from additional provisions in this instrument.

The declaration text contains no express offence provisions, fines, or administrative penalties. Clause 5 declares the described activity to be a quality assurance activity to which Part VC of the Health Insurance Act 1973 applies. Consequently, any penal, enforcement or protective consequences hinge on the content of Part VC of the Act rather than on the instrument’s words. The instrument itself neither creates nor specifies enforcement processes.

What the instrument does claim about legal effect

• Declaration of Part VC application: Clause 5 connects the ACGR to the Part VC legal framework. The precise enforcement or immunity provisions that Part VC supplies are not set out in this instrument; they must be sourced from the Health Insurance Act 1973 itself.

• Repeal mechanism tied to the Act: Clause 4 states the instrument “is repealed when it ceases to be in force in accordance with subsection 124X(4) of the Health Insurance Act 1973.” This ties the duration and termination of the declaration to the Act’s provisions. Any enforcement related to premature or improper continuance would therefore rely on the Act’s machinery.

What the instrument does not do

• The declaration does not identify the body responsible for enforcement of Part VC obligations or protections; it does not specify sanctions for breaches of data submission obligations (which are described as voluntary), failure to obtain consent, or failures in reporting.

• The Schedule describes governance (Advisory Board, Southern Adelaide HREC) but these are oversight and review mechanisms; the instrument does not give them statutory enforcement powers in this text. Instead, the HREC’s role is described as methodological oversight and regular review.

Practical consequence for regulated parties

• Entities and individuals cannot rely on this instrument alone to ascertain penalties, immunities or enforcement processes that will apply to the ACGR. To determine what legal consequences follow from the declaration, a reader must consult Part VC of the Health Insurance Act 1973 (the statutory regime into which this declaration places the registry) for the relevant enforcement and protection provisions.

• Because the Schedule describes submissions as voluntary, enforcement of data submission is not an immediate feature of the declared activity as recorded. Any compulsory consequences (for example, protections that might shield quality assurance materials from disclosure) or enforcement mechanisms (for example, sanctions for misuse) are matters for Part VC and not stated here.

In short, penalties and enforcement are not set out in the declaration text; the instrument’s legal effect is to import the declared activity into the statutory framework of Part VC, with enforcement implications to be read from the Act.

The declaration explicitly connects the ACGR and its operations to several statutory and administrative contexts.

• Health Insurance Act 1973, Part VC: Clause 3 states the instrument is made under subsection 124X(1) of the Health Insurance Act 1973 and clause 5 declares the Schedule activity to be a quality assurance activity to which Part VC applies. The instrument therefore interacts directly with the Act’s Part VC regime. The text does not restate or summarise Part VC; it imports whatever legal effects, protections, or obligations Part VC contains for declared quality assurance activities.

• Australian Institute of Health and Welfare (AIHW) and National Death Index linkage: The Schedule requires that a minimum dataset be submitted to the AIHW at five-year intervals for linkage with the National Death Index (Schedule 1). This establishes a statutory data flow between the ACGR and AIHW for mortality linkage processes, contingent on recipient consent. Thus the registry interfaces with national health statistics and mortality data systems via AIHW.

• DonateLife, National Organ and Tissue Donation and Transplantation Authority, and MSAC: The Schedule identifies these Australian government bodies as recipients of de-identified aggregated ACGR outputs. The declaration therefore situates the registry within the administrative ecosystem of organ and tissue donation, transplantation policy and medical services advisory processes. The instrument does not specify what statutory duties these bodies have in respect of the registry outputs; it simply names them as recipients.

• Human research and ethics oversight: The Southern Adelaide Human Research Ethics Committee is named as the oversight body that reviews the ACGR’s methods. While the declaration does not specify the legal force of HREC determinations, it places the registry under an established research ethics review process, linking it to broader research governance frameworks.

• Data privacy and de-identification: The Schedule states outcomes are “always reported in a de-identified, aggregated form.” The instrument therefore anticipates interaction with privacy-protective practices and regulatory expectations. The text does not invoke the Privacy Act or other privacy laws directly, and it does not prescribe technical de-identification standards; it describes the output format as de-identified and aggregated.

• Institutional relationships: The ACGR is conducted by Flinders University staff. This establishes a contractual and institutional connection between the university and the identified regulatory and advisory bodies. The declaration therefore creates an institutional interface between a university-hosted registry and Commonwealth statutory apparatus (via Part VC and named recipient bodies).

Limits of interaction described in the instrument

• The declaration does not set out how conflicts between the ACGR’s practices and other statutes would be resolved, nor does it specify data-sharing protocols beyond AIHW linkage and the stated recipients of de-identified outputs. Practical compliance with other laws (for example, state-based health records laws, privacy laws, or public records legislation) is not discussed in the instrument.

• The instrument is careful to limit the declaration to the extent the activity “relates to health services provided in Australia” (clause 5). That territorial qualification constrains the scope of application and interaction with extraterritorial data flows or non-Australian health services.

To understand the full legal interactional map, one must read this declaration alongside Part VC of the Health Insurance Act 1973, AIHW and National Death Index data-sharing rules, the Southern Adelaide HREC governance framework, and any applicable privacy and health records legislation. The declaration records specific linkages (AIHW, DonateLife, etc.) and commits to de-identified aggregated reporting as the form of external disclosure.

The instrument contains limited internal amendment history but provides a few explicit pointers to prior and future change.

• Date and authorisation: The declaration is dated 19 November 2025 and signed by Professor Michael Kidd AO as the Minister’s delegate. That date is the instrument’s creation date and is the one recorded date in the text.

• Commencement rule and “as originally made” note: Clause 2 contains a commencement table that states the whole instrument commences the day after registration. The note beneath that table says: “This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.” That language means the instrument documents its original commencement arrangements and does not purport to reflect subsequent amendments in the commencement table itself.

• Repeal rule tied to the Act: Clause 4 provides that the instrument “is repealed when it ceases to be in force in accordance with subsection 124X(4) of the Health Insurance Act 1973.” This delegates the question of duration and repeal mechanics to the Act’s subsection 124X(4). The declaration therefore does not set a fixed expiry date itself; instead, its life-cycle is governed by the Act.

• Reference to a prior declaration: The Schedule contains the sentence “Since previous declaration, the ACGR has included further datasets related to new forms of corneal transplantation and is moving towards more secure online submission of register data...” That phrase confirms there was at least one earlier declaration covering the ACGR. The current instrument therefore follows previous instrument(s) and reflects changes to the registry’s datasets and submission systems since the prior declaration. The instrument does not reproduce those earlier texts or provide a statutory history; it merely acknowledges prior declarations and operational changes.

• No internal amendment text: The declaration contains no schedules or clauses that amend earlier instruments directly. It sets out the current description and governance of the ACGR as the basis for this declaration. Any later alterations to the declared description, or to the status of the ACGR as a declared quality assurance activity, would be handled by subsequent instruments or amendments under the Act.

• Practical amendment route: Because the instrument is made under subsection 124X(1), amendments to the declaration would in practice require a further instrument made under the same statutory power. The instrument does not outline a bespoke amendment procedure; it adheres to the usual pattern in which the relevant statutory power is exercised to make, vary or repeal such declarations.

For a complete legislative amendment history, one would need to examine past declarations under s 124X and the Act’s records of declared activities. The declaration itself establishes current content, notes evolution since an earlier declaration, and relies on the Act for commencement and repeal rules rather than embedding fixed amendment or expiry dates within its text.

The declaration text contains no reference to any litigation, court decisions, or legal disputes concerning the ACGR, the declaration process, or Part VC. The instrument does not name any judicial authority, case law, or precedent. Where the Schedule says “Since previous declaration,” it does not link to any litigation history; it reports only operational changes.

Implications

• No litigation record in instrument: Because no litigation is recorded in the declaration, there is no source-grounded basis in this text for stating whether the ACGR or its declaration has been or is subject to legal challenge.

• Potential for litigation not addressed: The instrument does not flag areas of known dispute or controversy that might prompt litigation. That absence does not prove a lack of litigation historically; it simply indicates the declaration as made does not record any litigation history.

• Where to look for litigation information: To investigate litigation concerning the ACGR, the declaration’s attachment to Part VC suggests relevant proceedings, if any, would involve interpretation of Part VC of the Health Insurance Act 1973, or perhaps privacy and data-sharing disputes involving AIHW linkage or HREC oversight. The declaration, however, provides no particulars and does not themselves identify any cases.

In summary, the instrument states no litigation history, names no cases, and does not record judicial rulings. Any assertion about prior litigation would require sources outside this declaration.

The Schedule and short Part 1 provisions reveal several practical points that actors should note, each grounded in the text.

1. Voluntary contribution and incomplete coverage: The Schedule states that the ACGR “collects information on a voluntary basis” and records current participation at “80-85%.” That means the registry does not capture every corneal transplant in Australia; analyses and outputs are based on voluntary submissions and thus reflect partial coverage. Users of registry outputs should therefore account for voluntary sampling in interpreting aggregate results.

2. Consent is clinician-mediated: Consent is obtained from graft recipients by their surgeon and is indicated on the registration form. The operational pathway for consent therefore depends on clinicians properly offering, recording, and submitting consented registrations. If clinicians fail to seek or record consent, records will not enter the registry. The ability of recipients to withdraw consent “at any time” further complicates longitudinal completeness.

3. AIHW five-year linkage contingent on consent: The Schedule requires a minimum dataset be submitted to AIHW “at 5-year intervals, for linkage with the National Death Index.” This linkage occurs only for consented records. Practically, mortality linkage for outcome ascertainment will be limited to those patients who consented to AIHW submission, and the five-year cadence means mortality information may be incorporated at multi-year intervals, not continuously.

4. Follow-up cadence and loss to follow-up: The Schedule describes follow-up data collection at 12-18 month and 12-36 month intervals, continues until graft failure, death, or loss to recipient. The text therefore anticipates varying follow-up intervals and potential long durations of follow-up. Maintaining contact with recipients or their treating health practitioners over many years can be administratively demanding and creates risk of attrition (loss to follow-up), which the Schedule recognises.

5. Reported outputs are de-identified and aggregated: The Schedule states “Outcomes from the ACGR are always reported in a de-identified, aggregated form.” While the text affirms the output format, it does not specify de-identification standards, thresholds, or technical methods. Recipients of underlying data (for approved purposes) and registry designers must therefore be explicit about how de-identification is achieved in practice.

6. Changes in data collection and participation tied to submission method: The Schedule records surgeon feedback that paper-based forms are a barrier to participation, and states a move to secure online submission is expected to raise registration rates “substantially.” The expected increase is an operational assumption recorded in the Schedule; it introduces risk that unless online systems are implemented effectively, participation may remain below desired levels. It also raises procurement, security and usability issues in implementing secure online submission.

7. Limited donor data: The Schedule notes collection of “limited data about cornea donors.” The scope and granularity of donor information is therefore constrained; analyses that require more extensive donor information may not be possible from ACGR data as described.

8. Governance overlay: The Advisory Board and Southern Adelaide HREC provide oversight and review. While this is governance assurance, it also introduces procedural timelines and compliance gates: methodological changes may require HREC review and Advisory Board approval, which can slow the implementation of new datasets or changes to submission practices.

9. No penalties stated: The instrument does not contain penalties or enforcement measures for non-compliance with voluntary submission. Entities cannot rely on the declaration text to establish compulsory duties or sanctions tied to the registry itself.

10. Territorial limitation: Clause 5 limits the declaration to the extent the quality assurance activity “relates to health services provided in Australia.” Cross-border transplant cases or data from overseas providers will not fall within the declared scope unless they relate to Australian health services.

Each of these points is a concrete operational or interpretive “gotcha” arising directly from the instrument’s language and the Schedule’s statements. They prescribe where implementers, data users and legal advisers should focus attention: sample completeness, consent capture, data linkage timing, de-identification practice, submission method implementation, governance timelines, and the limited legal content regarding enforcement.

Compliance with the declared activity, as described, involves operational practices consistent with the Schedule’s duties and rights. The declaration imports Part VC of the Health Insurance Act 1973 by reference; to determine statutory compliance obligations or to claim any legal protections under Part VC, entities must read Part VC alongside this instrument. The Schedule, however, describes the core operational steps to participate and to align with the ACGR’s processes.

For surgeons and clinical teams

• Obtain and record consent: Prior to submitting any registry data, obtain explicit consent from graft recipients and record it on the ACGR registration form as required by the Schedule. Ensure the registration form used matches the ACGR’s current version and captures whether the patient has consented to AIHW five-yearly linkage.

• Inform patients of withdrawal rights: Explain to recipients that they may withdraw consent and be removed from the registry at any time; establish a process to record withdrawals and to transmit withdrawal notifications promptly to the registry administrators to ensure records are removed or marked per registry practice.

• Submit the specified datasets: Provide the demographic recipient data, limited donor data and surgical procedure information the ACGR requests. Keep documentation on what fields are required and how to complete them. Anticipate the registry moving to secure online submission; prepare local IT governance and privacy checks to facilitate online uploads.

• Respond to follow-up requests: Be prepared to respond to ACGR follow-up requests, which are sent at 12-18 month and 12-36 month intervals, and continue until graft failure, recipient death, or loss to follow-up. Establish clinic processes to collect and forward follow-up information in the formats the ACGR requires.

For Eye Banks and other contributing health professionals

• Coordinate data provision: Determine which parts of the requested dataset you hold and have procedures to supply those data on a voluntary basis to the ACGR. Confirm data formats with Flinders University staff and align with secure submission processes as they are introduced.

For Flinders University staff and registry administrators

• Maintain governance and HREC engagement: Continue management under an Advisory Board of clinicians and scientists and maintain regular review of methods by the Southern Adelaide Human Research Ethics Committee as described. Document HREC approvals and Board minutes to evidence adherence to oversight.

• Implement secure online submission: The Schedule records that moving away from paper-based forms to secure online submission is expected to substantially increase participation. Implement secure, user-friendly online submission platforms with appropriate authentication, encryption and data-handling controls. Ensure the platform supports consent capture and withdrawal workflows and interfaces reliably with local clinical systems where feasible.

• Manage AIHW linkage processes: Prepare and maintain the minimum dataset required for five-yearly submission to AIHW for linkage with the National Death Index. Ensure linkage submissions are performed only for records where recipients have consented. Maintain records of datasets submitted and consents attached.

• De-identification and reporting: Ensure that all external outputs are de-identified and aggregated as the Schedule requires. Maintain documentation on de-identification methods used, including rationale and any risk assessments, so that published outputs follow the declared “always reported in a de-identified, aggregated form” rule.

• Recordkeeping for consent and withdrawals: Maintain auditable records of consent capture and withdrawal. Establish processes to remove or suppress records promptly when a recipient withdraws consent.

For legal and compliance officers

• Read Part VC: Determine what statutory protections, confidentiality rules or disclosure limitations Part VC confers on declared quality assurance activities. The declaration itself does not create or explain statutory immunities; those are in the Act.

• Privacy and data-sharing alignment: Although the Schedule mandates de-identified aggregated reporting, ensure registry practices meet applicable privacy and health records obligations. Document how de-identification standards align with any regulatory expectations, and confirm lawful bases for any transfers to AIHW and other named recipients under prevailing privacy frameworks.

• Prepare for governance reviews: Anticipate that changes in datasets, methods or submission modes will involve the Advisory Board and Southern Adelaide HREC. Plan for timeframes associated with ethical review and Board approval when proposing changes.

For recipients of ACGR outputs (Eye Banks, DonateLife, MSAC, international community)

• Use aggregate outputs within stated limits: Recognise the outputs are de-identified and aggregated. Analyse their applicability given the voluntary coverage (80-85% at the time of declaration) and the limitations on donor data.

• Clarify data requests that would require individual-level information: If a recipient body requires identifiable or line-level data, plan to approach the registry administrators and the relevant ethical and legal authorities, recognising that the Schedule describes only de-identified aggregated reporting for general outputs.

Cross-cutting practical steps

• Establish clear SOPs: For all participating entities, develop standard operating procedures that set out consent capture, data submission (paper and online), follow-up workflows, withdrawal handling, record retention and data security.

• Audit trails and logging: Maintain audit trails for data submissions, consent records and linkages to AIHW so that any questions about provenance, consent and data flows can be answered.

• Training for clinicians: Provide training for surgeons and clinic staff on how to explain registry participation and withdrawal rights to patients, how to complete registration forms, and how to respond to follow-up questionnaires.

• Prepare for transition to online systems: Coordinate with IT and clinical governance to ensure online tools are compatible with clinic workflows and privacy/security policies.

These compliance steps are grounded in the Schedule’s description of the ACGR’s operations: consent obtained by surgeons and recorded on the registration form; voluntary data collection from Eye Banks, surgeons and other health professionals; AIHW five-year linkage; HREC oversight; de-identified aggregated reporting; and a planned shift to secure online submissions to increase participation.